Breast imaging with fluorine-18-FDG PET: Quantitative image analysis

Journal of Nuclear Medicine

Volumn 38, Issue 8, 1997, Pages 1186-1191

  Avril, Norbert ^a   Bense, Sandra ^b   Ziegler, Sibylle I ^a   Dose, Jörg ^b   Weber, Wolfgang ^a   Laubenbacher, Christian ^b   Römer, Wolfgang ^b   Jänicke, Fritz ^a   Schwaiger, Markus ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Breast cancer; Fluorine 18 FDG; PET; Quantitative image analysis

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; BREAST TUMOR; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; IMAGE ANALYSIS; ISOTOPE LABELING; MAJOR CLINICAL STUDY; MAMMOGRAPHY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

BREAST DISEASES; BREAST NEOPLASMS; DEOXYGLUCOSE; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MIDDLE AGED; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; ROC CURVE; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0030763016     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Kubota K, Matsuzwana T, Amemiya A, et al. Imaging of breast cancer with F-18 fluorodeoxyglucose and positron emission tomography. J Comput Assist Tomogr 1989;13:1097-1098.
2. Minn H, Soini I. (18-F) Fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer. Eur J Nucl Med 1989;15:61-66.
3. Wahl RL, Cody RL, Hutchins GD, et al. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]fluoro-2-deoxy-D-glucose. Radiology 1991;179:765-770.
4. Tse YN, Hoh CK, Hawkins RA, et al. The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. Ann Surg 1992:11:359-377.
5. Nieweg ON, Kim EE, Wong W-H, et al. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer 1993;71:3920-3925.
6. Hoh CK, Hawkins RA, Glaspy JA, et al. Cancer detection with whole-body PET using 2-[18-F]fluoro-2-deoxy-D-glucose. J Comput Assist Tomogr 1993;17:582-589.
7. Adler LP, Crowe JP, Al-Kaisi NK, et al. Evaluation of breast masses and axillary lymph nodes with (F-18) 2-deoxy-2-fluoro-D-glucose PET. Radiology 1993;187:743750.
8. Avril N, Dose J, Jänicke F, et al. Metabolie characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose. J Clin Oncol 1996; 14: 1848-1857.
9. Kopans DB, Meyer JE, Sadowsky N. Breast Imaging. N EnglJ Med 1984;310:960967.
10. Patlak CS, Blasberg RG, Ferastermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Metab 1983:3:1-7.
11. DiChiro G, Brooks RA. PET quantitation: blessing and curse. J Nucl Med 1988;29: 1603-1604.
12. Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med 1991:32:623-648.
13. Hawkins RA, Choi Y, Huang S-C, et al. Quantitating tumor glucose metabolism with FDG and PET. J Nucl Med 1992;33:339-344.
14. Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology 1993;189:847-850.
15. Kim CK, Gupta NC, Chandramouli B, et al. Standardized uptake values of FDG: body surface area correction is preferable to body weight correction. J Nucl Med 1994;35: 164-167.
16. Hamberg LM, Hunter GJ, Alpert NM, et al. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med 1994;35: 1308-1312.
17. Löwe VJ, Hoffmann JM, DeLong DM, et al. Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. J Nucl Med 1994;35:1771-1776.
18. Keyes JWJ. SUV: standard uptake or silly useless value? J Nucl Med 1995;36:18361839.
19. Minn H, Joesuu H, Ahonen A, et al. Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo; comparison with DNA flow cytometry in head and neck tumors. Cancer 1988 ;61:1776-1781.
20. Strauss LG, Clorius JH, Schlag P. et al. Recurrence of colorectal tumors: PET evaluation. Radiology 1989; 170:329-332.
21. Knopp MV, Strauss LG. Haberkorn U, et al. Optimizing therapy management in unresectable bronchiogenic carcinoma by metabolic imaging with PET. J Nucl Med 1990;31:766.
22. Haberkorn U. Strauss LG, Dimitrakopoulou A, et al. PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. ./ Nucl Med 1991:32:1485-1490.
23. Langen K-J, Braun U, Kops ER, et al. The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucosc uptake in bronchial carcinomas. J Nucl Med 1993;34: 355-359.
24. Laubenbacher C. Saumweber D, Wagner-Manslau C, et al. Comparison of fluorine18-fluorodeoxyglucose PET, MRI and endoscopy for staging of head and neck squamous-cell carcinomas. J Nucl Med 1995;36:I747-1757.
25. Harnacher K, Coenen HH, Stöcklin G. Efficient stereospecific synthesis of nocarrieradded 2-(F-18)-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986;27:235-238.
26. Weber W, Schad D, Römer W. et al. Fluorine-18 FDG-PET in solitary pulmonary nodules: determination of tumor size and correction of partial volume effect. J Nucl Med 1995;36:95P.
27. Schad D, Ziegler S, Weber W, et al. Quantitative Ermittlung der Aktivitätskonzentration von tumor-PET-Datensätzen mittels automatischer Grö§enBestimmung und Partialvolumenkorrektur [J. Nuklearmedizin 1996;35:A89.
28. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36.
29. Metz CE. Basic principles of ROC analysis. Semin Nucl Med 1978;8:283-298.
30. Gallagher BM, Fowler JS, Gutterson NI, et al. Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of (18F) 2-deoxy-2-fluoro-D-glucose. J Nucl Med 1978; 19:1154-1161.
31. Sokoloff L, Reivich M, Kennedy C, et al. The fC-14] deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure and normal values in the conscious and anesthetized albino rat. J Neurochem 1977;28:897-916.
32. Buxton DB, Scheiben HR. Measurement of regional glucose metabolic rates in reperfused myocardium. Am J Physiol 1991;261:2058-2068.
33. Ng CK, Holden JE, DeGrado TR, et al. Sensitivity of myocardial fluorodeoxyglucose lumped constant to glucose and insulin. Am J Physiol 1991;260:593-603.
34. Wahl RL, Henry CA, Ethier SP. Serum glucose: effects on tumor and normal tissue accumulation of 2-[F-18]-fluoro-2-deoxy-D-glucose FDG in rodents with mammary carcinoma. Radiology 1992; 183:643-647.
35. Kubota R, Yamada S, Kubota K, et al. Intratumoral distribution of fluorine-18fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissue studied by microautoradiography. J Nucl Med 1992;33:1972-1980.
36. Blomqvist G, Lammertsma AA, Mazoyer B, et al. Effect of tissue heterogeneity on quantification in positron emission tomography. Eur J Nucl Med 1995;22:652-663.
37. Zasadny K.R, Kison PV, Quint LE, et al. Quantification of systematic distorsion in nonattenuation corrected FDG-PET images in patients with untreated lung cancer. J Nucl Med 1995;36:5P.
38. Hoffmann EJ, Huang S, Phelps ME. Quantitation in positron emission computed tomography: effect of object size. J Comput Assist Tomogr 1979;3:299-308. :